Neuberger Berman Group LLC cut its position in shares of Sanofi SA (NYSE:SNY) by 28.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 47,721 shares of the company’s stock after selling 18,662 shares during the quarter. Neuberger Berman Group LLC’s holdings in Sanofi were worth $2,132,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. Girard Partners LTD. acquired a new stake in Sanofi during the third quarter valued at approximately $154,000. Stratos Wealth Partners LTD. acquired a new stake in Sanofi during the third quarter valued at approximately $174,000. Quantum Capital Management acquired a new stake in Sanofi during the third quarter valued at approximately $202,000. Holderness Investments Co. acquired a new stake in Sanofi during the third quarter valued at approximately $204,000. Finally, New England Research & Management Inc. acquired a new stake in Sanofi during the third quarter valued at approximately $205,000. 7.04% of the stock is currently owned by institutional investors and hedge funds.
NYSE:SNY opened at $42.77 on Wednesday. Sanofi SA has a 1 year low of $37.43 and a 1 year high of $45.86. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85. The company has a market capitalization of $108.88 billion, a PE ratio of 13.66, a PEG ratio of 2.41 and a beta of 0.67.
Sanofi (NYSE:SNY) last posted its earnings results on Wednesday, October 31st. The company reported $1.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.09. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The company had revenue of $9.39 billion during the quarter, compared to analysts’ expectations of $9.10 billion. During the same quarter in the previous year, the company posted $1.71 earnings per share. Sanofi’s quarterly revenue was up 1.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Sanofi SA will post 3.1 EPS for the current year.
A number of equities research analysts have weighed in on SNY shares. Jefferies Financial Group raised Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, December 11th. Zacks Investment Research raised Sanofi from a “sell” rating to a “hold” rating in a report on Tuesday, September 11th. Argus lifted their target price on shares of Sanofi from $48.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, November 8th. Barclays upgraded shares of Sanofi from an “underweight” rating to an “equal weight” rating in a research note on Thursday, November 1st. Finally, Morgan Stanley initiated coverage on shares of Sanofi in a research note on Friday, December 14th. They issued an “equal weight” rating for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the company. Sanofi presently has a consensus rating of “Hold” and an average target price of $50.00.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Recommended Story: Coverage Ratio
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.